Maxim downgraded Moleculin Biotech (MBRX) to Hold from Buy. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders’ Hot Stocks on TipRanks >> Read More on MBRX: Moleculin Biotech Gains European Approval for Phase 3 Trial Moleculin Biotech receives first approval in Europe for AML trial recruiting Moleculin Biotech Launches MIRACLE Study for AML Moleculin Biotech Shares Updates on MIRACLE Trial Moleculin Biotech Shares Corporate Presentation Update Disclaimer & DisclosureReport an Issue
